Abstract
Sodium glucose co-transporter 2 (SGLT2) inhibitors are a new class of anti-diabetic medications. Canagliflozin was the first drug approved in this group in 2013 and subsequently dapagliflozin was approved in January 2014 and empagliflozin was approved in August 2014. Preclinical studies have demonstrated safety, tolerability, and efficacy in terms of glycemic control and HbA1c level in type 2 diabetes mellitus (T2DM) patients in comparison to other anti-diabetic drugs. The U.S. Food and Drug Administration (FDA) recently released a warning that some of the patients who used SGLT2 inhibitors developed diabetic ketoacidosis (DKA). Empagliflozin has showed safety in type 2 diabetics with renal impairment. Each of these medications can be used as a single treatment or in combination with other anti-diabetic medications.
Keywords: Anti-hyperglycemic agents, dipeptidyl peptidase-4 inhibitors, fasting plasma glucose, sulphonylureas, sodium glucose co-transporter 2 inhibitors, SGLT2, type 1 diabetes mellitus, type 2 diabetes mellitus, urinary glucose excretion.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:A Review of Sodium Glucose Co-transporter 2 Inhibitors Canagliflozin, Dapagliflozin and Empagliflozin
Volume: 13 Issue: 2
Author(s): Saad Hussain Syed, Sucheta Gosavi, Waseem Shami, Marco Bustamante, Zul Farah, Muhammad Teleb, Aamer Abbas, Sarmad Said and Debabrata Mukherjee
Affiliation:
Keywords: Anti-hyperglycemic agents, dipeptidyl peptidase-4 inhibitors, fasting plasma glucose, sulphonylureas, sodium glucose co-transporter 2 inhibitors, SGLT2, type 1 diabetes mellitus, type 2 diabetes mellitus, urinary glucose excretion.
Abstract: Sodium glucose co-transporter 2 (SGLT2) inhibitors are a new class of anti-diabetic medications. Canagliflozin was the first drug approved in this group in 2013 and subsequently dapagliflozin was approved in January 2014 and empagliflozin was approved in August 2014. Preclinical studies have demonstrated safety, tolerability, and efficacy in terms of glycemic control and HbA1c level in type 2 diabetes mellitus (T2DM) patients in comparison to other anti-diabetic drugs. The U.S. Food and Drug Administration (FDA) recently released a warning that some of the patients who used SGLT2 inhibitors developed diabetic ketoacidosis (DKA). Empagliflozin has showed safety in type 2 diabetics with renal impairment. Each of these medications can be used as a single treatment or in combination with other anti-diabetic medications.
Export Options
About this article
Cite this article as:
Syed Hussain Saad, Gosavi Sucheta, Shami Waseem, Bustamante Marco, Farah Zul, Teleb Muhammad, Abbas Aamer, Said Sarmad and Mukherjee Debabrata, A Review of Sodium Glucose Co-transporter 2 Inhibitors Canagliflozin, Dapagliflozin and Empagliflozin , Cardiovascular & Hematological Agents in Medicinal Chemistry 2015; 13 (2) . https://dx.doi.org/10.2174/1871525714666151106121215
DOI https://dx.doi.org/10.2174/1871525714666151106121215 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Self-management of Diabetes in Children and Young Adults Using Technology and Smartphone Applications
Current Diabetes Reviews Long-lasting Insulin Treatment Via a Single Subcutaneous Administration of Liposomes in Thermoreversible Pluronic® F127 Based Hydrogel
Current Pharmaceutical Design Relations between GPR4 Expression, Microvascular Density (MVD) and Clinical Pathological Characteristics of Patients with Epithelial Ovarian Carcinoma (EOC)
Current Pharmaceutical Design Proteomic Analysis of Liver Diseases: Molecular Mechanisms and Biomarker Discovery
Mini-Reviews in Medicinal Chemistry A Case Report: Euglycemic Diabetic Ketoacidosis Presenting as Chest Pain in a Patient on a Low Carbohydrate Diet
Current Diabetes Reviews Translating the Potential of Stem Cells for Diabetes Mellitus: Challenges and Opportunities
Current Stem Cell Research & Therapy The Impact of a New Best Practice Advisory on the Management of Diabetic Ketoacidosis
Current Diabetes Reviews Contemporary Roles of the Pediatric Psychologist in Diabetes Care
Current Diabetes Reviews Saxagliptin: A New Drug for the Treatment of Type 2 Diabetes
Mini-Reviews in Medicinal Chemistry An Update on the Roles of the Complement System in Autoimmune Diseases and the Therapeutic Possibilities of Anti-Complement Agents
Current Drug Therapy Phenomenology and Neurobiology of Childhood Onset Schizophrenia
Current Psychiatry Reviews Oral Hypoglycemics: A Review of Chemicals Used to Treat Type 2 Diabetes
Current Bioactive Compounds Common and Less Common Peripheral Nerve Disorders Associated with Diabetes
Current Diabetes Reviews Evaluation of Early Administration of Insulin Glargine in the Acute Management of Diabetic Ketoacidosis
Current Diabetes Reviews Serum Insulin Degrading Enzyme Level and Other Factors in Type 2 Diabetic Patients with Mild Cognitive Impairment
Current Alzheimer Research Recommendations for Severe Hypertriglyceridemia Treatment, are there New Strategies?
Current Vascular Pharmacology Peptide Immunotherapies in Type 1 Diabetes: Lessons from Animal Models
Current Medicinal Chemistry An Overview of Valuable Scientific Models for Diabetes Mellitus
Current Diabetes Reviews Menstrual Cycle and Glycemic Control
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Status of Stem Cell Based Clinical Trials in the Treatment for Diabetes
Current Diabetes Reviews